The NIHR Advanced Therapy Medicinal Product (ATMP) Group includes clinical leaders from across the NIHR and key UK stakeholder organisations. Our key partners are listed on this page.
Advanced Therapy Treatment Centres (ATTC) operate within the NHS framework and are coordinated by the Cell and Gene Therapy Catapult to address the unique and complex challenges of bringing pioneering advanced therapy medicinal products (ATMPs) to patients.
Accelerated Access Collaborative (AAC) is a unique partnership between patient groups, government bodies, industry and NHS bodies, working together to streamline the adoption of new innovations in healthcare. AAC aims to provide a more joined up approach, at all stages, to ensure the best, new innovations reach patients faster.
British Society for Cell and Gene Therapy (BSGCT) aims to accelerate scientific progress and promote ethical and thorough transfer of gene- and cell-based technologies from the laboratory into the clinic.
Cell and Gene Therapy Catapult is a centre of excellence in innovation, with the core purpose of building a world-leading cell and gene therapy sector in the UK as a key part of a global industry. They are supported by Innovate UK to drive the growth of the industry by helping cell and gene therapy organisations across the world translate early stage research into commercially viable and investable therapies.
London Advanced Therapies (LAT) Network consists of three higher education institutions (HEIs); King's College London, Imperial College London and University College London. LAT uses the Advanced Therapies’ complementary expertise and strengths at each of the institutions in the collaboration to provide a comprehensive set of activities to catalyse knowledge exchange between the HEIs, Small and Medium sized Enterprises (SMEs) and industry.
Genetic Alliance UK is a national charity working to improve the lives of patients and families affected by genetic, rare and undiagnosed conditions. They are an alliance of over 200 patient organisations.
The Pan UK ATMP Pharmacy Working Group for ATMPs acts as an expert and informed body to support the activities of UK Pharmacies to facilitate ATMP usage. The group consists of pharmacists from across the UK that specialise in the governance, prescribing, administration and monitoring of ATMPs and is an excellent example of collaboration across the NHS. The aims of the group are to promote good practice, identify and resolve pharmacy issues to maximise the effectiveness and development of services for hospitals to administer advanced therapies.
The Cell Therapy Facility is a partnership between the Queens University of Belfast and Belfast Health and Social Care Trust. The Cell Therapy Facility is able to provide storage of ATMPs, manipulation of ATMPs for administration to patients and clinical trial expertise in the development of cell based therapies.
The UK Clinical Research Facility (UKCRF) Network supports CRFs by providing best practice guidance and tools to ensure each CRF delivers clinical trials of the highest standard.